NATCO Pharma announced that Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH (together, �Fresenius�) have filed a complaint against Natco Pharma USA LLC f/k/a Dash Pharmaceuticals LLC in the District Court of Delaware relating to the marketing of Dash Pharmaceuticals Diazepam Injection prefilled syringe in the United States. Fresenius has not yet effectuated service of the complaint which is required to commence the lawsuit. Natco Pharma intends to defend the matter accordingly. Dash Pharmaceuticals LLC had been acquired by Natco Pharma, Inc. and Dash Pharmaceuticals LLC had changed its name to Natco Pharma USA LLCPowered by Capital Market - Live News

Natco Pharma has received a warning letter dated 08 April 2024 from the United States Food and Drug Administration (USFDA) for its Kothur (Pharma Division) manufacturing facility. The Company does not believe that the warning letter will have an impact on disruption of supplies or existing revenues from this facility. It may cause delay/withholding of pending product approvals from this site.Powered by Capital Market - Live News

Net profit of Natco Pharma rose 241.41% to Rs 212.70 crore in the quarter ended December 2023 as against Rs 62.30 crore during the previous quarter ended December 2022. Sales rose 54.03% to Rs 758.60 crore in the quarter ended December 2023 as against Rs 492.50 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales758.60492.50 54 OPM %35.3421.50 - PBDT300.50122.90 145 PBT256.3081.40 215 NP212.7062.30 241 Powered by Capital Market - Live News

Natco Pharma announced that the Board of Directors of the Company at its meeting held on 14 February 2024, inter alia, have recommended the dividendinterim of Rs 1.25 per equity Share (i.e. 62.5%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Natco Pharma will hold a meeting of the Board of Directors of the Company on 14 February 2024.Powered by Capital Market - Live News